Hypercoagulability - Market Insight, Epidemiology, and Market Forecast - 2034
상품코드:1506952
리서치사:DelveInsight
발행일:On Demand Report
페이지 정보:영문 200 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
앞으로 몇 년동안, 응고증 시장은 이 질환에 대한 인식이 높아지고 전 세계 의료비 지출이 증가함에 따라 변화할 것으로 예상됩니다.
기업과 연구기관들은 응고장애 연구개발에 영향을 미칠 수 있는 과제를 평가하고 기회를 모색하기 위해 노력하고 있습니다. 개발 중인 치료법은 질환을 치료/개선하기 위한 새로운 접근법에 초점을 맞추었습니다. 주요 기업들은 응고장애 치료법 개발에 참여하고 있습니다. 새로운 치료법의 등장은 응고증 치료제 시장에 큰 영향을 미칠 것으로 예상됩니다.
이 보고서는 주요 7개국의 응고증 시장을 조사했으며, 시장 개요와 함께 역학, 환자 동향, 새로운 치료법, 2034년까지 시장 규모 예측, 미충족 의료 수요 등을 제공합니다.
목차
제1장 중요 인사이트
제2장 응고증에 대한 주요 요약
제3장 응고성 강화 경쟁 정보 분석
제4장 응고증: 시장 개요
제5장 응고증: 질환의 배경 및 개요
서론
징후와 증상
병태생리학
위험 요인
진단
제6장 환자 동향
제7장 응고증의 역학과 환자군
역학 주요 조사 결과
전제 및 근거 : 주요 7개 국가
역학 시나리오 : 주요 7개 국가
미국
유럽 5개국
일본 역학
제8장 치료 알고리즘, 현재의 치료법 및 의료행위
제9장 미충족 욕구
제10장 응고증 치료의 주요 평가 항목
제11장 시판 제품
제12장 새로운 치료법
제13장 응고제 : 주요 7개국 시장 분석
제14장 속성 분석
제15장 주요 7개국 : 시장 전망
미국 : 시장 규모
유럽 5개국 : 시장 규모 및 전망
독일 시장 규모
프랑스 시장 규모
이탈리아 시장 규모
스페인 시장 규모
영국 시장 규모
일본 시장 규모
제16장 응고증의 접근 및 상환 개요
제17장 KOL의 견해
제18장 시장 성장 촉진요인
제19장 시장의 장벽
제20장 부록
제21장 DelveInsight의 서비스 내용
제22장 면책사항
제23장 DelveInsight에 대해
LSH
영문 목차
영문목차
DelveInsight's "Hypercoagulability - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Hypercoagulability market report provides current treatment practices, emerging drugs, Hypercoagulability market share of the individual therapies, current and forecasted Hypercoagulability market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Hypercoagulability treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered:
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2020-2034
Hypercoagulability Disease Understanding and Treatment Algorithm
The DelveInsight Hypercoagulability market report gives a thorough understanding of the Hypercoagulability by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Hypercoagulability.
Treatment
It covers the details of conventional and current medical therapies available in the Hypercoagulability market for the treatment of the condition. It also provides Hypercoagulability treatment algorithms and guidelines in the United States, Europe, and Japan.
Hypercoagulability Epidemiology
The Hypercoagulability epidemiology division provide insights about historical and current Hypercoagulability patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Hypercoagulability epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.
Country Wise-Hypercoagulability Epidemiology
The epidemiology segment also provides the Hypercoagulability epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Hypercoagulability Drug Chapters
Drug chapter segment of the Hypercoagulability report encloses the detailed analysis of Hypercoagulability marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Hypercoagulability clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Marketed Drugs
The report provides the details of the marketed product available for Hypercoagulability treatment.
Hypercoagulability Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Hypercoagulability treatment.
Hypercoagulability Market Outlook
The Hypercoagulability market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Hypercoagulability market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Hypercoagulability market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Hypercoagulability market in 7MM is expected to change in the study period 2020-2034.
Key Findings
This section includes a glimpse of the Hypercoagulability market in 7MM.
The United States Market Outlook
This section provides the total Hypercoagulability market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Hypercoagulability market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Hypercoagulability market size and market size by therapies in Japan is also mentioned.
Hypercoagulability Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Hypercoagulability market or expected to get launched in the market during the study period 2020-2034. The analysis covers Hypercoagulability market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Hypercoagulability Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Hypercoagulability key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Hypercoagulability emerging therapies.
Reimbursement Scenario in Hypercoagulability
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SME's opinion working in Hypercoagulability domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Hypercoagulability market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Hypercoagulability Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report:
The report covers the descriptive overview of Hypercoagulability, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Hypercoagulability epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Hypercoagulability are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Hypercoagulability market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hypercoagulability market
Report Highlights:
In the coming years, Hypercoagulability market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Hypercoagulability R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Hypercoagulability. Launch of emerging therapies will significantly impact the Hypercoagulability market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hypercoagulability
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Hypercoagulability Report Insights
Patient Population
Therapeutic Approaches
Hypercoagulability Pipeline Analysis
Hypercoagulability Market Size and Trends
Market Opportunities
Impact of upcoming Therapies
Hypercoagulability Report Key Strengths
11 Years Forecast
7MM Coverage
Hypercoagulability Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake
Hypercoagulability Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers
Key Questions:
Market Insights:
What was the Hypercoagulability market share (%) distribution in 2020 and how it would look like in 2034?
What would be the Hypercoagulability total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Hypercoagulability market size during the forecast period (2024-2034)?
At what CAGR, the Hypercoagulability market is expected to grow in 7MM during the forecast period (2020-2034)?
What would be the Hypercoagulability market outlook across the 7MM during the forecast period (2020-2034)?
What would be the Hypercoagulability market growth till 2032, and what will be the resultant market Size in the year 2034?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
What is the disease risk, burden and unmet needs of the Hypercoagulability?
What is the historical Hypercoagulability patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Hypercoagulability in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hypercoagulability?
Out of all 7MM countries, which country would have the highest prevalent population of Hypercoagulability during the forecast period (2020-2034)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
What are the current options for the Hypercoagulability treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Hypercoagulability in the USA, Europe, and Japan?
What are the Hypercoagulability marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Hypercoagulability?
How many therapies are developed by each company for Hypercoagulability treatment?
How many are emerging therapies in mid-stage, and late stage of development for Hypercoagulability treatment?
What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Hypercoagulability therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Hypercoagulability and their status?
What are the key designations that have been granted for the emerging therapies for Hypercoagulability?
What are the global historical and forecasted market of Hypercoagulability?
Reasons to buy:
The report will help in developing business strategies by understanding trends shaping and driving the Hypercoagulability market
To understand the future market competition in the Hypercoagulability market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Hypercoagulability in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Hypercoagulability market
To understand the future market competition in the Hypercoagulability market
Table of Contents
1. Key Insights
2. Executive Summary of Hypercoagulability
3. Competitive Intelligence Analysis for Hypercoagulability
4. Hypercoagulability: Market Overview at a Glance
4.1. Hypercoagulability Total Market Share (%) Distribution in 2020
4.2. Hypercoagulability Total Market Share (%) Distribution in 2034
5. Hypercoagulability: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Hypercoagulability Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Hypercoagulability Epidemiology Scenario in the 7MM (2020-2034)
7.4. United States Epidemiology
7.4.1. Hypercoagulability Epidemiology Scenario in the United States (2020-2034)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Hypercoagulability Epidemiology Scenario in Germany (2020-2034)
7.5.2. France Epidemiology
7.5.2.1. Hypercoagulability Epidemiology Scenario in France (2020-2034)
7.5.3. Italy Epidemiology
7.5.3.1. Hypercoagulability Epidemiology Scenario in Italy (2020-2034)
7.5.4. Spain Epidemiology
7.5.4.1. Hypercoagulability Epidemiology Scenario in Spain (2020-2034)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Hypercoagulability Epidemiology Scenario in the United Kingdom (2020-2034)
7.5.6. Japan Epidemiology
7.5.6.1. Hypercoagulability Epidemiology Scenario in Japan (2020-2034)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Hypercoagulability Treatment and Management
8.2. Hypercoagulability Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Hypercoagulability Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Hypercoagulability: Seven Major Market Analysis
13.1. Key Findings
13.2. Hypercoagulability Market Size in 7MM
13.3. Hypercoagulability Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Hypercoagulability Total Market Size in the United States
15.1.2. Hypercoagulability Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Hypercoagulability Total Market Size in Germany
15.3.2. Hypercoagulability Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Hypercoagulability Total Market Size in France
15.4.2. Hypercoagulability Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Hypercoagulability Total Market Size in Italy
15.5.2. Hypercoagulability Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Hypercoagulability Total Market Size in Spain
15.6.2. Hypercoagulability Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Hypercoagulability Total Market Size in the United Kingdom
15.7.2. Hypercoagulability Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Hypercoagulability Total Market Size in Japan
15.8.3. Hypercoagulability Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Hypercoagulability
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
The table of contents is not exhaustive; the final content may vary.
